India's Piramal adds capacity to U.S. high-potency API site

With an expansion, Piramal Pharma Solutions can now make HPAPIs with OELs down to 1mcg/m3 at the site it acquired from Ash Stevens. ( Ash Stevens )

India’s Piramal has intensified its focus on the U.S. market including buying an API producer in the Michigan several years ago. Now its CDMO, Piramal Pharma Solutions, has completed an expansion at that site where it makes high-potency active pharmaceutical ingredients (HPAPIs).

The company invested $10 million in the former Ash Stevens site in Riverview, Michigan, where it makes HPAPis with low exposure levels, adding two kilo labs as well as quality control and analysis labs. It is now capable of making HPAPIs with OELs down to 1mcg/m3.  

It has added nearly 50 jobs. It has 127 workers now but says it plans to soon have 150. 

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: Piramal bulks up in injectable generics, buying five drugs from J&J

“This new, enhanced capability opens the site up to a new base of customers, including the antibody drug conjugate (ADC) market,” Vince Ammoscato, Piramal VP and site head at Riverview, said in a statement

With demand for high-potency APIs growing, other CDMOs are scaling up in that arena as well. Cambrex in May opened new capacity at a site in Iowa. It can handle projects up to 300 kg. 

Piramal bought the Ash Stevens operations in 2016 for $53 million and milestones

 

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.